ABEC, a company involved in engineered solutions and services for biotech manufacturing, will deliver multiple Custom Single Run (CSR) single-use systems to Lilly’s next-generation biopharmaceutical manufacturing facility in Limerick, Ireland.

ABEC’s large-scale CSR Bioreactors will be at the heart of the facility, and ABEC will also manufacture, test, and install large-scale CSR GenMix systems. Equipment deliveries are scheduled for 3Q23.

Lilly selected ABEC to support Basis of Design (BOD) engineering of the facility’s upstream and downstream processes utilizing ABEC’s CSR technology. The BOD effort leveraged key CSR benefits in scale, performance, customizability, and supply chain security to meet Lilly’s design goals for the facility.

ABEC’s customized CSR systems allow Lilly to significantly leverage their extensive process and operations experience from other plants in their network, supporting rapid startup, high productivity, seamless technology transfer, and full regulatory compliance. The CSR Bioreactors’ superior mixing and mass transfer performance will enable Lilly’s high-density cell culture processes. The CSR GenMix systems will support large scale harvest and purification.

“ABEC is proud to be partnering with Lilly on this important project,” said Scott Pickering, ABEC CEO and Chairman. “We are pleased that our unique CSR products and customized, flexible approach will support Lilly’s vision for state-of-the-art manufacturing.”